Cancer Consultants Cancer News for Professionals

Carbogen and Nicotinamide Improves Survival of Patients with Advanced Bladder Cancer Receiving Radiotherapy

jmaxon@onco-ed.com (jenny maxon) — Wed, 11 Nov 2009 16:16:56 GMT

Researchers from the UK have reported that patients with locally advanced bladder cancer treated with concomitant carbogen, nicotinamide, and radical accelerated radiotherapy have a 13% improved three-year survival compared with patients treated with radiotherapy alone. The details of this Phase III randomized trial were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in the first week of November.

H-R3 (Nimotuzumab) Enhances Radiation and Chemotherapy Responses in Advanced Head and Neck Cancer

jmaxon@onco-ed.com (jenny maxon) — Wed, 11 Nov 2009 16:08:20 GMT

Researchers from India have reported that the addition of nimotuzumab to radiation therapy or radiation therapy plus chemotherapy increases long-term loco-regional control and survival in patients with advanced head and neck cancer. The details of this Phase IIB study were presented at the 2009 meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO).

Adjuvant Erbitux® May Improve Survival of High-risk Resected Head and Neck Cancer

jmaxon@onco-ed.com (jenny maxon) — Wed, 11 Nov 2009 15:55:39 GMT

Researchers affiliated with RTOG 0234 have reported that the addition of Erbitux® (cetuximab) may improve outcomes of patients with high-risk resected head and neck cancer receiving chemoradiotherapy. The details of this study were presented at the 2009 meeting of the American Society for Therapeutic Radiology and Oncology in the first week of November.

Radiotherapy and Hormonal Therapy Effective for Men with Prostate Cancer Failing Surgery

jmaxon@onco-ed.com (jenny maxon) — Tue, 10 Nov 2009 11:16:48 GMT

Researchers from the Mayo Clinic have reported that relapse-free survival was over 90% in patients treated with salvage radiotherapy (RT) plus two years of androgen deprivation therapy (ADT) for post-prostatectomy relapse. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology in the first week in November, 2009.

Autologous Stem Cell Transplant with Lentiviral (HIV) Vector Successful in Two Patients with Adrenoleukodystrophy

jmaxon@onco-ed.com (jenny maxon) — Tue, 10 Nov 2009 11:08:09 GMT

Researchers from France have reported the successful gene transfer, using a lentiviral vector, in two patients with X-linked adrenoleukodystrophy (ALD). The details of this study appeared in the November 6, 2009 issue of Science.

Erbitux® Improves Survival of Patients with Unresectable Head and Neck Cancer Receiving Radiation Therapy and Platinol®

jmaxon@onco-ed.com (jenny maxon) — Tue, 10 Nov 2009 10:56:59 GMT

Researchers affiliated with ECOG 3303 have reported that the addition of Erbitux® (cetuximab) to concurrent Platinol® (cisplatin) and radiotherapy improves progression-free survival (PFS) and overall survival (OS) in patients with unresectable head and neck cancer who had not been previously treated. The details of this Phase II study were presented at the 2009 meeting of the Association for Therapeutic Radiology and Oncology in the first week of November.

Gemzar® Effective for Peripheral T-cell Lymphomas and Mycosis Fungoides

jmaxon@onco-ed.com (jenny maxon) — Mon, 09 Nov 2009 15:24:06 GMT

Researchers from Italy have reported that Gemzar® (gemcitabine) is effective single-agent therapy for previously treated patients with peripheral T-cell lymphoma (PTCL) and mycosis fungoides (MF). The details of this study appeared in an early online publication in the Annals of Oncology on November 3, 2009.

Rituxan®-Fludara® Highly Effective for Extranodal MALT B-cell Lymphomas

jmaxon@onco-ed.com (jenny maxon) — Mon, 09 Nov 2009 15:15:16 GMT

Researchers from Spain have reported that Rituxan® (rituximab) and Fludara® (fludarabine) produces complete remissions in 90% of newly diagnosed patients with extranodal marginal-zone lymphomas of the mucosal-associated lymphoid tissue (MALT) type. The details of this study were published in the November 15, 2009 issue of Cancer.

Oncophage® Cancer Vaccine Shows Promise in Recurrent Glioblastoma

jmaxon@onco-ed.com (jenny maxon) — Mon, 09 Nov 2009 15:08:00 GMT

Researchers from the Brain Tumor Research Center at the University of California, San Francisco, have reported that Oncophage® (vitespen), a cancer vaccine, may improve survival of patients with recurrent or progressive high-grade glioblastoma. The details of this Phase II clinical trial were presented at the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons (AANS)/CNS section on tumors on October 24.

Vaccine Against HPV-16 Effective for Vulvar Intraepithelial Neoplasia

jmaxon@onco-ed.com (jenny maxon) — Fri, 06 Nov 2009 12:16:59 GMT

Researchers from the Netherlands have reported that vaccination with synthetic long-peptides against human papillomavirus (HPV)-16 was effective in treating vulvar intraepithelial neoplasia (VIN). The details of this study were published in the November 5, 2009 issue of the New England Journal of Medicine.